XZXiangyu Zhong

Xiangyu Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiangyu Zhong has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Xu

    Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

    11 shared publications
  • Jianjun Gao

    Department of General Surgery The 2nd Affiliated Hospital of Harbin Medical University Harbin China

    9 shared publications
  • Yunfu Cui

    Department of Pancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, China

    8 shared publications
  • Jiangang Wang

    Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, China

    6 shared publications
  • Qingfu Dong

    Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China

    6 shared publications
  • Canghai Guan

    Department of General Surgery The 2nd Affiliated Hospital of Harbin Medical University Harbin China

    5 shared publications

Latest Publications

  • Open Access

    Mitophagy in Hepatic Ischemia–Reperfusion Injury: From Mitochondrial Dysfunction to Therapeutic Targeting

    by Xinlei Zou, Tianjie Zhang, Nan Wang, Yuanyue Li, Xingming Jiang, Xiangyu Zhong

    Hepatic ischemia–reperfusion injury (HIRI) is a major cause of postoperative liver dysfunction and adverse outcomes in hepatectomy, liver transplantation, and hemorrhagic shock. Among the multiple mechanisms implicated in HIRI, mitochondria are recognized as central organelles that integrate metabolic failure, oxidative stress, inflammation, and cell death. During ischemia, interruption of oxygen and nutrient supply impairs oxidative phosphorylation, depletes ATP, disrupts ionic homeostasis, and renders mitochondria highly vulnerable to subsequent injury. Upon reperfusion, reoxygenation triggers excessive reactive oxygen species production, calcium overload, mitochondrial permeability transition pore opening, and release of damage-associated molecular patterns, thereby amplifying hepatocellular injury and sterile inflammatory responses. As a key component of mitochondrial quality control, mitophagy plays a context-dependent role in HIRI. Appropriate activation of mitophagy facilitates the clearance of damaged mitochondria, limits oxidative stress, restrains inflammasome activation, and preserves hepatocellular homeostasis, whereas insufficient or dysregulated mitophagy contributes to mitochondrial accumulation and aggravates liver injury. This review summarizes mitochondrial alterations during the ischemic and reperfusion phases, outlines the major mitophagy pathways involved in HIRI and discusses recent advances in upstream regulation, disease-specific dysregulation, and mitophagy-targeted interventions. A better understanding of the dynamic and biphasic nature of mitophagy in HIRI may provide a stronger theoretical basis for precision liver-protective strategies and future translational therapies.

  • Open Access

    The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransferase 2

    by Wujiang Shi, Xin Liu, Nan Wang, Qianwen Zhang, Jianjun Gao, Canghai Guan, Yapeng Li, Chengru Yang, Shaowu Bi, Xinlei Zou, et al.

    Aims: Metabolic dysfunction–associated steatotic liver disease (MASLD) represents one of the most common chronic liver disorders worldwide, and its incidence continues to rise each year. Serine β‐lactamase‐like protein (LACTB) is a serine protease that plays a crucial role in lipid metabolism and hepatocellular carcinoma, but its function in MASLD remains unclear. Therefore, the study aims to elucidate the effect and mechanism of LACTB in the progression of MASLD. Materials and methods: The expression of LACTB in liver tissues from MASLD patients and high‐fat diet (HFD) fed mice was assessed. Both in vivo and in vitro models were established to examine the role and molecular mechanisms of LACTB in MASLD. Results: LACTB protein levels were upregulated in the liver tissues from MASLD patients and HFD‐fed mice. LACTB overexpression exacerbated hepatic steatosis, insulin resistance, and inflammation in HFD‐fed mice. Conversely, LACTB knockdown improved these phenotypes. Mechanistically, LACTB interacted with CPT2 and promoted its ubiquitin‐mediated degradation. The effect of LACTB in hepatocellular lipid metabolism was dependent on CPT2. Conclusions: Our findings indicate that LACTB is a novel regulatory factor in MASLD by influencing the ubiquitin‐mediated degradation of CPT2 to participate in disease progression. These findings may provide a novel potential therapeutic strategy for MASLD.

  • Open Access

    Exosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications

    by Chengru Yang, Zhiyu Wang, Shaowu Bi, Xinmiao Zhang, Zhaoqiang Xu, Yifei Ge, Tianjie Zhang, Nan Wang, Yi Xu, Xiangyu Zhong

    Pancreatic cancer (PC) is an extremely aggressive cancer of the digestive system with insidious onset and the lack of effective biomarkers, resulting in late-stage diagnosis and poor prognosis. Exosomal non-coding RNAs (ncRNAs) are key mediators of intercellular communication that drive PC initiation and advancement. By modulating gene expression, they impact tumor microenvironment (TME) remodeling, proliferation, migration, apoptosis, and immune evasion. Critically, exosomal ncRNAs serve as promising biomarkers for early diagnosis and prognostic assessment. This review summarizes the current research achievements regarding exosomal ncRNAs in PC, systematically elaborating on their roles in tumor occurrence, metastasis, chemoresistance and the TME. Furthermore, by integrating the potential of exosomal ncRNAs in the diagnosis, treatment and prognosis of PC and by highlighting the challenges and future directions, this review aims to offer novel insights for future research and clinical translation of exosomal ncRNAs in PC.


  • Open Access

    Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology

    by Yifei Ge, Lixue Jiang, Chengru Yang, Qingfu Dong, Chengwu Tang, Yi Xu, Xiangyu Zhong

    Tumor-associated macrophages (TAMs) play a pivotal role in sculpting the tumor microenvironment and influencing cancer progression, particularly through their interactions with various forms of regulated cell death (RCD), including apoptosis, pyroptosis, ferroptosis, and necroptosis. This review examines the interplay between TAMs and these RCD pathways, exploring the mechanisms through which they interact to promote tumor growth and advancement. We examine the underlying mechanisms of these intricate interactions, emphasizing their importance in cancer progression and treatment. Moreover, we present potential therapeutic strategies for targeting TAMs and manipulating RCD to enhance anti-tumor responses. These strategies encompass reprogramming TAMs, inhibiting their recruitment, and selectively eliminating them to enhance anti-tumor functions, alongside modulating RCD pathways to amplify immune responses. These insights offer a novel perspective on tumor biology and provide a foundation for the development of more efficacious cancer therapies.


  • Open Access

    Research progress and applications of epigenetic biomarkers in cancer

    by Jianjun Gao, Wujiang Shi, Jiangang Wang, Canghai Guan, Qingfu Dong, Jialin Sheng, Xinlei Zou, Zhaoqiang Xu, Yifei Ge, Chengru Yang, et al.

    Epigenetic changes are heritable changes in gene expression without changes in the nucleotide sequence of genes. Epigenetic changes play an important role in the development of cancer and in the process of malignancy metastasis. Previous studies have shown that abnormal epigenetic changes can be used as biomarkers for disease status and disease prediction. The reversibility and controllability of epigenetic modification changes also provide new strategies for early disease prevention and treatment. In addition, corresponding drug development has also reached the clinical stage. In this paper, we will discuss the recent progress and application status of tumor epigenetic biomarkers from three perspectives: DNA methylation, non-coding RNA, and histone modification, in order to provide new opportunities for additional tumor research and applications.


  • Utilization of 3D printing technology in hepatopancreatobiliary surgery

    by Wujiang Shi, Jiangang Wang, Jianjun Gao, Xinlei Zou, Qingfu Dong, Ziyue Huang, Jialin Sheng, Canghai Guan, Yi Xu, Yunfu Cui, et al.

    The technology of three-dimensional (3D) printing emerged in the late 1970s and has since undergone considerable development to find numerous applications


  • Open Access

    Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma

    by Chengru Yang, Qingfu Dong, Haolin Bao, Yifei Ge, Zhaoqiang Xu, Jinglin Li, Xingming Jiang, Yi Xu, Xiangyu Zhong

    Pancreatic cancer is a malignancy that affects the digestive tract and has a low 5-year survival rate of lower than 15%. Owing to its genetic mutation and metabolic complexity, pancreatic cancer is difficult to treat with surgical resection, radiotherapy, and chemotherapy. The predominant modality of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), primarily attributed to mutations in KRAS gene. Ferroptosis, an iron-mediated reactive oxygen species (ROS)-elevated nonapoptotic cell death caused by lipid peroxidation, is distinct from any other known type of cell death. Ferroptosis is closely related to the occurrence and progression of different types of cancers, including PDAC. Previous research has demonstrated that ferroptosis not only triggers cell death in PDAC and hampers tumor growth but also enhances the effectiveness of antitumor medications. In our review, we mainly focus on the core mechanism of ferroptosis, reveal its interrelationship with PDAC, and illustrate the progress of ferroptosis in different treatment methods of PDAC.


  • Open Access

    Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

    by Jianjun Gao, Jiangang Wang, Canghai Guan, Wujiang Shi, Qingfu Dong, Jialin Sheng, Xinlei Zou, Zhaoqiang Xu, Yifei Ge, Ziyue Huang, et al.

    Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a notably poor prognosis. A large number of patients with PDAC develop metastases before they are diagnosed with metastatic pancreatic cancer (mPDAC). For mPDAC, FOLFIRINOX or gemcitabine plus nab-paclitaxel are the current first-line treatments. It is important to note, however, that many patients will fail chemotherapy because of drug resistance. ​Heterogeneous tumors and complex tumor microenvironments are key factors. As a result, clinical researchers are exploring a variety of alternative treatment modalities. Current understanding of the molecular signature and immune landscape of PDAC has motivated the emergence of different targeted and immune-based therapeutic approaches, some of which have shown promising results. The purpose of this review is to discuss the new targets and new drugs for mPDAC in terms of specific pathogenic factors such as metabolic vulnerability, DNA damage repair system, tumor microenvironment and immune system, in order to identify potential vulnerabilities in mPDAC patients and hopefully improve the prognosis of mPDAC patients.


  • Open Access

    Cullin-associated and neddylation-dissociated protein 1 (CAND1) alleviates NAFLD by reducing ubiquitinated degradation of ACAA2

    by Xiang Huang, Xin Liu, Xingda Li, Yang Zhang, Jianjun Gao, Ying Yang, Yuan Jiang, Haiyu Gao, Chongsong Sun, Lina Xuan, et al.

    Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with high morbidity and mortality. The current study aims to explore the role of Cullin-associated and neddylation-dissociated protein 1 (CAND1) in the development of NAFLD and the underlying mechanisms. CAND1 is reduced in the liver of NAFLD male patients and high fat diet (HFD)-fed male mice. CAND1 alleviates palmitate (PA) induced lipid accumulation in vitro. Hepatocyte-specific knockout of CAND1 exacerbates HFD-induced liver injury in HFD-fed male mice, while hepatocyte-specific knockin of CAND1 ameliorates these pathological changes. Mechanistically, deficiency of CAND1 enhances the assembly of Cullin1, F-box only protein 42 (FBXO42) and acetyl-CoA acyltransferase 2 (ACAA2) complexes, and thus promotes the ubiquitinated degradation of ACAA2. ACAA2 overexpression abolishes the exacerbated effects of CAND1 deficiency on NAFLD. Additionally, androgen receptor binds to the −187 to −2000 promoter region of CAND1. Collectively, CAND1 mitigates NAFLD by inhibiting Cullin1/FBXO42 mediated ACAA2 degradation.


  • Open Access

    Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies

    by Qingfu Dong, Haolin Bao, Jiangang Wang, Wujiang Shi, Xinlei Zou, Jialin Sheng, Jianjun Gao, Canghai Guan, Haoming Xia, Jinglin Li, et al.

    In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the stage of liver fibrosis is associated with an increased risk of severe liver-related and cardiovascular events and is the strongest predictor of mortality in MAFLD patients. More and more people believe that MAFLD is a multifactorial disease with multiple pathways are involved in promoting the progression of liver fibrosis. Numerous drug targets and drugs have been explored for various anti-fibrosis pathways. The treatment of single medicines is brutal to obtain satisfactory results, so the strategies of multi-drug combination therapies have attracted increasing attention. In this review, we discuss the mechanism of MAFLD-related liver fibrosis and its regression, summarize the current intervention and treatment methods for this disease, and focus on the analysis of drug combination strategies for MAFLD and its subsequent liver fibrosis in recent years to explore safer and more effective multi-drug combination therapy strategies.